WO2004106938A3 - Agents de diagnostic et de therapie pour des maladies associees au p2y recepteur purique 7 couple a une proteine g (p2y7) - Google Patents

Agents de diagnostic et de therapie pour des maladies associees au p2y recepteur purique 7 couple a une proteine g (p2y7) Download PDF

Info

Publication number
WO2004106938A3
WO2004106938A3 PCT/EP2004/005558 EP2004005558W WO2004106938A3 WO 2004106938 A3 WO2004106938 A3 WO 2004106938A3 EP 2004005558 W EP2004005558 W EP 2004005558W WO 2004106938 A3 WO2004106938 A3 WO 2004106938A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
purinoreceptor
therapeutics
diagnostics
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/005558
Other languages
English (en)
Other versions
WO2004106938A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Ralf Thiele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2004106938A2 publication Critical patent/WO2004106938A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004106938A3 publication Critical patent/WO2004106938A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un P2Y7 humain associé à des troubles urologiques et de reproduction, à des maladies neurologiques, respiratoires et hématologiques, au cancer, aux maladies gastro-intestinales et hépatiques, aux inflammations, aux maladies endocrinologiques et cardio-vasculaires. La présente invention porte également sur des tests pour identifier des composés utiles au traitement ou à la prévention de troubles urologiques et de reproduction, de maladies neurologiques, respiratoires et hématologiques, du cancer, de maladies gastro-intestinales et hépatiques, d'inflammations, de maladies endocrinologiques et cardio-vasculaires. Cette invention concerne aussi des composés qui se lient au P2Y7 et/ou activent ou inhibent son activité, ainsi que des compositions pharmaceutiques contenant ces composés.
PCT/EP2004/005558 2003-06-02 2004-05-24 Agents de diagnostic et de therapie pour des maladies associees au p2y recepteur purique 7 couple a une proteine g (p2y7) Ceased WO2004106938A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03012495.2 2003-06-02
EP03012495 2003-06-02

Publications (2)

Publication Number Publication Date
WO2004106938A2 WO2004106938A2 (fr) 2004-12-09
WO2004106938A3 true WO2004106938A3 (fr) 2008-01-17

Family

ID=33483901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005558 Ceased WO2004106938A2 (fr) 2003-06-02 2004-05-24 Agents de diagnostic et de therapie pour des maladies associees au p2y recepteur purique 7 couple a une proteine g (p2y7)

Country Status (1)

Country Link
WO (1) WO2004106938A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359362A1 (en) * 2001-11-07 2003-05-19 Millennium Pharmaceuticals, Inc. Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
WO2001040802A2 (fr) * 1999-12-02 2001-06-07 Glaxo Group Limited Nouvelle proteine
US6348574B1 (en) * 1992-11-17 2002-02-19 Icos Corporation Seven transmembrane receptors
WO2002030949A2 (fr) * 2000-10-13 2002-04-18 Genaissance Pharmaceuticals, Inc. Haplotypes du gene ltb4r
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
US20030017530A1 (en) * 1997-10-14 2003-01-23 Christer Owman Heptahelix receptor and its use as leukotriene B4 receptor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
US6348574B1 (en) * 1992-11-17 2002-02-19 Icos Corporation Seven transmembrane receptors
US20030017530A1 (en) * 1997-10-14 2003-01-23 Christer Owman Heptahelix receptor and its use as leukotriene B4 receptor
WO2001040802A2 (fr) * 1999-12-02 2001-06-07 Glaxo Group Limited Nouvelle proteine
WO2002030949A2 (fr) * 2000-10-13 2002-04-18 Genaissance Pharmaceuticals, Inc. Haplotypes du gene ltb4r
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COHEN N ET AL: "RECENT PROGRESS IN THE DEVELOPMENT OF LEUKOTRIENE B4 ANTAGONISTS", 1994, CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, PAGE(S) 13-22, ISSN: 0967-8298, XP000650716 *

Also Published As

Publication number Publication date
WO2004106938A2 (fr) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005103702A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur 2 de la chimiokine cxc (cxcr2)
WO2004106938A3 (fr) Agents de diagnostic et de therapie pour des maladies associees au p2y recepteur purique 7 couple a une proteine g (p2y7)
WO2004104574A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 7 (ccr7)
WO2005040822A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 25 couple a la proteine g (gpr25)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2004106937A3 (fr) Diagnostic et therapeutique pour des maladies associees au recepteur 6 de purine p2y (p2y6) couple a la proteine g
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005040829A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)
WO2005040824A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 24 couple a la proteine g (gpr24)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2004106936A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au purinorecepteur p2y9 couple aux proteines g
WO2004104595A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)
WO2004086052A3 (fr) Produits de diagnostic et de therapeutique pour des maladies liees au recepteur de l'adenosine a2b couple a la proteine g (adora2b)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005003762A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 2 couple a la proteine g specifique aux neurones sensoriels (snsr2)
WO2004082572A3 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase